<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700411</url>
  </required_header>
  <id_info>
    <org_study_id>POACC-1</org_study_id>
    <nct_id>NCT03700411</nct_id>
  </id_info>
  <brief_title>Influence of Opioid Analgesia on Circulating Tumor Cells in Open Colorectal Cancer Surgery</brief_title>
  <acronym>POACC-1</acronym>
  <official_title>Influence of Peri-operative Opioid Analgesia on Circulating Tumor Cells in Patients Undergoing Open Colorectal Cancer Surgery - Multi-center, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Institute of Molecular and Translational Medicine, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>General University Hospital, Prague</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tomas Bata Hospital, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Novy Jicin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Institute of Molecular and Translational Medicine, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effects of three types of perioperative analgesia on the number of circulating
      tumor cells following radical colorectal cancer surgery. To find correlations with other
      perioperative factors and clinical/pathological disease characteristics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in number of circulating tumor cells prior to surgery to 4 weeks after surgery</measure>
    <time_frame>1 - 3 days before surgery to 4 weeks after surgery</time_frame>
    <description>Baseline number of circulating tumor cells will be recorded prior to surgery in a venous blood sample. Number of circulating tumor cells will be measured 4 weeks after surgery in a venous blood sample. These two values will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain assessment</measure>
    <time_frame>3 days postoperatively</time_frame>
    <description>Pain intensity assessed using Numerical Rating Scale (0-10)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Circulating Tumor Cell</condition>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine-based perioperative analgesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Piritramid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Piritramid-based perioperative analgesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epidural</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Perioperative epidural analgesia containing an opioid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Morphine intravenous</description>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piritramid</intervention_name>
    <description>Piritramid intravenous</description>
    <arm_group_label>Piritramid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epidural</intervention_name>
    <description>Perioperative epidural analgesia</description>
    <arm_group_label>Epidural</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing open radical surgery for colorectal cancer

          -  age over 18 years

          -  signed informed consent

        Exclusion Criteria:

          -  intolerance of the study drugs

          -  history of CRC surgery

          -  neoadjuvant therapy

          -  contraindications to epidural analgesia

          -  other malignancy not in permanent remission

          -  chronic opioid medication or opioid administration within 7 days preoperatively

          -  immunosuppressive or corticosteroid therapy

          -  surgery within 30 days preoperatively (except minor)

          -  chronic or acute infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marian Hajduch, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Molecular and Translational Medicine, Palacky University, Olomouc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emil Berta, MD PhD</last_name>
    <phone>00420608801303</phone>
    <email>e.berta@email.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Josef Srovnal, MD PhD</last_name>
    <phone>00420585632111</phone>
    <email>srovnalj@upol.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>T. Bata Regional Hospital Zlin</name>
      <address>
        <city>Zlin</city>
        <state>Jihomoravsky Kraj</state>
        <zip>76275</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Gabrhelik, MD, PhD</last_name>
      <phone>+420577552280</phone>
      <email>Tomas.Gabrhelik@bnzlin.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Máca, MD PhD</last_name>
      <phone>‭+420603728998‬</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>General University Hospital</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Michalek, MD PhD</last_name>
      <phone>‭+420602776261‬</phone>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Institute of Molecular and Translational Medicine, Czech Republic</investigator_affiliation>
    <investigator_full_name>Marian Hajduch, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Perioperative analgesia</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Circulating Tumor Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Pirinitramide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

